Condition (MeSH)
Hyperlipoproteinemias
ClinicalTrials.gov lists 327 trials for Hyperlipoproteinemias or a narrower condition beneath it. Merck Sharp & Dohme LLC has the most among industry and government lead sponsors, with 16.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 more section with rows
30 of the 327 trials are tagged with Hyperlipoproteinemias itself; the rest are tagged with a narrower condition beneath it.
When did Hyperlipoproteinemias trials start? (31)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 21
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 16 |
| 2025 | 14 |
| 2024 | 21 |
| 2023 | 18 |
| 2022 | 17 |
| 2021 | 18 |
| 2020 | 11 |
| 2019 | 19 |
| 2018 | 12 |
| 2017 | 18 |
Showing 10 of 31 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 17 trials starting in 2026 and about 17 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 30 trials still running at the 2026-10-09 snapshot; registered median of 19 months across 197 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hyperlipoproteinemias trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 26 |
| Phase 1/2 | 7 |
| Phase 2 | 44 |
| Phase 2/3 | 8 |
| Phase 3 | 82 |
| Phase 4 | 15 |
| Not applicable | 55 |
| Observational | 86 |
| Expanded access | 4 |
How many Hyperlipoproteinemias trials are recruiting? (11)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 10 |
| Recruiting | 44 |
| Enrolling by invitation | 6 |
| Active, not recruiting | 14 |
| Available | 1 |
Showing 5 of 11 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hyperlipoproteinemias trials? (12)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 16 |
| Novartis Pharmaceuticals | 14 |
| Organon and Co | 11 |
| Arrowhead Pharmaceuticals | 8 |
| Pfizer | 7 |
Showing 5 of 12 sponsors.
Which drugs are being tested for Hyperlipoproteinemias? (8)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| ATORVASTATIN | 13 |
| Evolocumab | 10 |
| ROSUVASTATIN | 9 |
| Ezetimibe | 9 |
| Lomitapide | 8 |
Showing 5 of 8 drugs.
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Inclisiran (Leqvio®) 300mg | 9 |
| Torcetrapib/Atorvastatin | 6 |
| Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) | 5 |
| ER Niacin | 4 |
| Niacin (+) laropiprant | 4 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hyperlipoproteinemias trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Coronary artery disease | 195 | 20 |
| Angina pectoris | 170 | 21 |
| Acute myocardial infarction | 162 | 18 |
| Angina unstable | 152 | 18 |
| Pneumonia | 123 | 14 |
Showing 5 of 10 adverse events.
Which publications cover Hyperlipoproteinemias? (63)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial. | JAMA | 2023 | Yes |
| Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. | JAMA | 2022 | Yes |
| Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4. | Journal of the American College of Cardiology | 2021 | Yes |
| Association of an HDL Apolipoproteomic Score With Coronary Atherosclerosis and Cardiovascular Death. | Journal of the American College of Cardiology | 2019 | Yes |
| Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels. | Atherosclerosis. Supplements | 2015 | Yes |
Showing 5 of 63 publications.
Sub-conditions in MeSH (5)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.